英睿迪完成新一轮融资，纽尔利资本领投

Core Insights - INREEDI has completed a new round of financing amounting to several tens of millions of RMB, led by NRL Capital [1] - The funds raised will primarily be used to accelerate the market promotion of the core product BeaShape RF therapy device, expand clinical research for new indications, and develop subsequent product pipelines [1] Company Overview - INREEDI is a medical device R&D company focused on low-temperature RF technology, having successfully launched multiple RF energy devices based on its self-developed technology platform [1] - The company has obtained several Class III medical device registration certificates and has a core team of industry experts with an average of over 15 years of experience [1] - INREEDI aims to innovate from the underlying technology to provide RF therapy solutions that combine "professional-level efficacy" with "consumer-level experience," exemplified by its core product BeaShape [1] Investment Perspective - NRL Capital emphasizes its ongoing focus on innovations in the medical technology sector, highlighting INREEDI's strong technical foundation and international R&D vision as core advantages [2] - The clinical data of the BeaShape product demonstrates excellent comfort and significant effectiveness, showcasing strong competitive differentiation in the market [2] - NRL Capital believes INREEDI has the potential to become a benchmark enterprise in the wave of domestic innovative consumer medical devices and a significant player in the global RF medical device field [2]